These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30009649)

  • 41. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and effectiveness of adalimumab in Japanese patients with juvenile idiopathic arthritis: Results from a real-world postmarketing study.
    Takei S; Iwata N; Kobayashi I; Igarashi T; Yoshinaga Y; Matsubara N; Sunaga N; Ito A; Yokota S
    Mod Rheumatol; 2021 Mar; 31(2):421-430. PubMed ID: 32340508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
    Fleischmann R; Connolly SE; Maldonado MA; Schiff M
    Arthritis Rheumatol; 2016 Sep; 68(9):2083-9. PubMed ID: 27111089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.
    Burmester GR; Kivitz AJ; Kupper H; Arulmani U; Florentinus S; Goss SL; Rathmann SS; Fleischmann RM
    Ann Rheum Dis; 2015 Jun; 74(6):1037-44. PubMed ID: 24550168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
    Kaeley GS; MacCarter DK; Pangan AL; Wang X; Kalabic J; Ranganath VK
    J Rheumatol; 2018 Dec; 45(12):1628-1635. PubMed ID: 30173153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
    Haraoui B; Cividino A; Stewart J; Guérette B; Keystone EC
    BMC Musculoskelet Disord; 2011 Nov; 12():261. PubMed ID: 22093579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
    Aletaha D; Maa JF; Chen S; Park SH; Nicholls D; Florentinus S; Furtner D; Smolen JS
    Ann Rheum Dis; 2019 Dec; 78(12):1609-1615. PubMed ID: 31434637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
    Ørnbjerg LM; Østergaard M; Jensen T; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Hetland ML; ; Slot O; Nielsen LK; Skjødt H; Majgaard O; Lorenzen T; Horn HC; Kowalski M; Johansen IL; Pedersen PM; Manilo N; Bliddal H
    Clin Rheumatol; 2017 Apr; 36(4):781-789. PubMed ID: 27921185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
    Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.
    Yamanaka H; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Tanaka Y; Suzuki H; Shinmura Y; Koike T
    Mod Rheumatol; 2015 Jul; 25(4):495-502. PubMed ID: 25487291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.
    Kanbori M; Suzuka H; Yajima T; Kishino E; Morishige R; Momohara S; Kawakami A; Ota M
    Mod Rheumatol; 2018 Jan; 28(1):66-75. PubMed ID: 28585869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
    Takeuchi T; Nakajima R; Komatsu S; Yamazaki K; Nakamura T; Agata N; Igarashi A; Tango T; Tanaka Y
    Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.